.avif)
Alnylam Email Format
Biotechnology Research
・
2,501-5,000 employees
・
Cambridge, MA, USA
Alnylam is a leading biopharmaceutical company pioneering RNA interference therapeutics to silence disease-causing genes, with six approved medicines treating rare and prevalent diseases worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@alnylam.com
Company Overview
Industry
Biotechnology Research
Founded
2002
Headquarters
Cambridge, MA, USA
Revenue
$1B-$2.5B
FUNDING Stage
Public
Website
Key Executives
Yvonne Greenstreet (Chief Executive Officer), Jeff Poulton (Chief Financial Officer), Timothy Maines (Chief Technical Operations and Quality Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Alnylam?
Alnylam uses the firstinitiallast format, so Jane Smith would be jsmith@alnylam.com.
What approved medicines does Alnylam currently sell?
Alnylam's commercial portfolio includes AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran), all RNAi therapeutics targeting conditions such as ATTR amyloidosis, acute hepatic porphyria, and primary hyperoxaluria.
How many employees does Alnylam have in 2026?
Alnylam has approximately 2,832 employees in 2026, operating out of its headquarters in Cambridge, MA. Tools like Clay can help you find and verify specific Alnylam contacts if you are building a targeted outreach list.
Who is the CEO of Alnylam?
Yvonne Greenstreet is the Chief Executive Officer of Alnylam. Other key leaders include Jeff Poulton as Chief Financial Officer and Timothy Maines as Chief Technical Operations and Quality Officer.
What is the Alnylam 2030 strategy focused on?
Alnylam's 2030 strategy centers on three pillars: achieving global TTR market leadership with products like AMVUTTRA and next-generation candidate nucresiran, growing through sustainable RNAi innovation across new tissue types, and expanding to more than 40 clinical programs by 2030.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating